INmune Bio Inc
INMB
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.02M
Close$
$0.83
63.1% downside
Current Fair Value
63.1% downsideOvervalued by 63.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $59.02 Million |
|---|---|
| Enterprise Value | $42.01 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.86 |
| Beta | 0.94 |
| Outstanding Shares | 26,718,507 |
Return
| Return on Equity | -90.44% |
|---|---|
| Return on Assets | -68.60% |
| Return on Invested Capital | 46.35% |
Valuation & Multiples
| P/E Ratio | -3.22 |
|---|---|
| PEG | 3.39 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 4.33 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$1.16 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4126▼ 29.71% |
|---|---|
| Total Calls | 69,800▲ 58.28% |
| Total Puts | 28,800▼ 7.99% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.27%▼ 3.96% |
|---|---|
| Total Invested | $7.33M▲ 20.37% |
| Investors Holding | 87▲ 1.00% |
ESG Score
No data